Cambridge Healthtech Institute’s 6th Annual
Implementing Risk-Based Monitoring – Part 2
Strategy, Data and Technology Solutions for RBM
February 20-21, 2020
Risk-based monitoring (RBM) approaches promise to improve clinical trial efficiency while ensuring data quality. As industry adoption of RBM increases, it is critical to reflect on lessons learned to refine the process, as well as focus on leveraging
RBM data for clinical operations. CHI’s 6th Annual Implementing Risk-Based Monitoring – Part 2 conference offers case studies and practical solutions from across pharma on effectively implementing clinical quality and RBM, as well as a
prospective look into the future of RBM.
Arrive early and attend Part 1 (Wed - Thurs): Implementing Risk-Based Monitoring – Part 1
Final Agenda
Day 1 | Day 2 | Download Brochure
Thursday, February 20
11:30 am Registration Open
12:30 pm Bridging Luncheon Presentation (Sponsorship Opportunity Available) or Enjoy Lunch on Your Own
1:00 Coffee and Dessert Break in the Exhibit Hall
2:00 Afternoon Plenary Keynotes
3:10 Booth Crawl & Refreshment Break in the Exhibit Hall. Last Chance for Exhibit Viewing
4:10 Chairperson’s Remarks
Christopher Biddle, Associate Director, Risk Management and Central Monitoring, The Janssen Pharmaceutical Companies
of J&J
4:15 RBQM – Establishing an End-to-end Quality Management Approach to Enable Risk-Based Solutions in Any Organization
Lynne Cesario,
Risk Based Monitoring Program Lead, Clinical Sciences and Operations, Global Product Development, Pfizer
4:45 Taking RBM for a Test Drive – How Trying before You Buy It Can Optimize Deployment Success
Rachel Lewis, Director,
Project Management, Project Management Office, Global Clinical Trial Operations, Merck
Selection of the optimal RBM technology solution to ensure clinical data quality and maximum efficiency is critical for implementation success in any company. However, with the rapid growth in solutions available, how do you choose the right one?
We will discuss the advantages, disadvantages and considerations for conducting a pilot of multiple solutions using internal study data to drive sound selection and optimize deployment success.
5:15 Presentation to be Announced
5:45 PANEL DISCUSSION: Moving Past the “i” in RBM: Partnership, Oversight, and Achieving Common Goals between Sponsor, CRO and Vendor
Co-Moderators:
Sarah Bednarski, Associate Director, Strategic Monitoring, Clinical Operations, Sunovion Pharmaceuticals
Gayle Hamilton,
Associate Director, Risk Based Monitoring, Project Operations and Business Performance, IQVIA
Panelists: Speakers of the Day
There are a variety of factors that may be complicating how sponsors, CROs and vendors work together in the RBM space: the formalized R2 requirement for “oversight”, the continuous evolution of RBM, the move past home-grown pilots, etc.
There’s more than one right way to implement RBM, but in the outsourced model, establishing a common goal and a way to work together are both critical to success.
- What are your goals with RBM? This is an interesting opportunity to hear how goals differ between CROs, vendors and sponsors.
- If you were to go back to when you first starting working with your CRO/vendor/sponsor knowing what you know now, what would you do differently? E.g. Hold a combined training session; hold an expectations meeting with best practices from prior
experiences; etc.
- What successes have you had? What are you still working on improving?
- In a collaboration between sponsor and CRO/vendor, what roles are important? E.g. Study team roles, specific functions, process-level roles across studies, etc.
- What, if any, limitations on transparency exist from CRO/vendor to sponsor or from sponsor to CRO/vendor, and have those limitations been overcome in some way?
6:15 Networking Reception
7:15 Close of Day
Day 1 | Day 2 | Download Brochure
Friday, February 21
7:15 am Registration Open
7:45 Breakfast Presentation to be Announced
Jill
Johnston President, Study Planning & Site Optimization, WCG
8:15 Session Break
8:20 Chairperson’s Remarks
Steve Young, CSO, Management, CluePoints
8:25 Risk-Based Monitoring in 2020: What Practical Lessons Can Veteran Companies Share?
Moderator:
Laurie Halloran, CEO, Halloran Consulting Group
Panelists: Carrie
Melvin, Vice President, Global Clinical Sciences and Delivery TA Head of Oncology, GSK/TESARO
Vinod Parthasarathy, Senior Director, MC2 Global Monitoring & Clinical Operations (Japan & China), Medtronic
Caro Unger, Senior Clinical
Operations Standards and Innovation Manager, Clovis Oncology
Laura Whitmore, Head, Clinical Operations, Oversight, Cerevel Therapeutics
The FDA’s guidance on Risk-Based Monitoring has been in use since August 2013, and the ICH E6 R2 has recently pushed the issue of using risk-based approaches to streamline the overly complex processes that cost life sciences sponsors so much
and add so little. But, given that we tend to wrestle with “the way it’s always been done” – how has the adoption been progressing in both early adopters and companies new to the more expanded use of technology to enhance
their adoption of risk-based approaches? On our panel, we will discuss how companies have fared and what practical lessons can be shared to facilitate adoption by other companies using the right-sized approach.
- How has trial design evolved in a risk-based approach?
- What is different in start-up: selection of sites and vendors, training of the entire team?
- If you aren’t doing it now, what is holding you back?
- The centralized monitoring role: What should we know to set up and manage the effort?
- Are there lessons learned and best practices that can be shared around remote site and even remote patient visits?
9:55 Presentation to be Announced
10:25 Networking Coffee Break
10:55 Chairperson’s Remarks
Janis Little, Vice President, Global R&D Quality, Allergan
11:00 Assessing Your Clinical Quality Management System: A Comprehensive Review of TransCelerate’s CQMS Assessment Tool
Janis Little, Vice
President, Global R&D Quality, Allergan
This session will help attendees assess clinical Quality Management Sessions to adhere to ICH E6R2 and prepare for future renovations and modernization of E6 and E8.
11:30 Quality Risk Management Framework: Guidance for Successful Implementation of Risk Management in Clinical Development
Allan Chow, PharmD, Senior Manager, Quality & Compliance Risk Management, Amgen
Effective quality risk management is fundamental to ensuring the protection of human subjects and reliability of clinical trial results during the conduct of clinical trials. Quality risk management supports effective delivery of clinical development
programs and ultimately delivery of treatments to patients. Thus, risk management is a core element of an effective quality management system (QMS) as described in the TransCelerate Clinical Quality Management System (CQMS) conceptual framework.
12:00 pm Transition to Shared Sessions
Chairperson’s Remarks
Neil Weisman, President, Continuum Clinical
12:05 The Connected Patient: A “One Stop Shop” for Trial Information and Data
Megan McBride, MPH, Associate Director, Janssen Clinical Innovation, GCDO, R&D, Janssen, The Pharmaceutical Companies of Johnson & Johnson
Learn how we are creating a connected experience for trial participants before, during and after the trial where patients can access meaningful information, their individual data to share with their EHR, aggregate study results and provide ongoing
feedback and insights to ensure a better experience for patients, caregivers and the site teams. Explore the possibilities to remain connected via communities to raise awareness around trials. The audience can gain insights as to the ins and
outs of how we managed to create a platform to share data directly with patients – from legal, privacy, regulatory and other key stakeholder hurdles to our vision for broadening the scope of data sharing across industry.
12:35 INTERACTIVE PANEL: Translating Virtual to Reality: Decentralized Trial Transformation
Moderator: Jane Myles, Head, Operational Intelligence and Innovation, Roche
Panelists: Darcy Forman, Vice President, Clinical Operations, Science37
Hassan Kadhim, Director, Clinical Trial Business Capabilities, GCO, Bristol-Myers Squibb
Carrie Melvin,
Vice President, Global Clinical Sciences and Delivery TA Head of Oncology, GSK/TESARO
Megan McBride, MPH, Associate Director, Janssen Clinical Innovation, GCDO, R&D, Janssen, The Pharmaceutical Companies of Johnson & Johnson
Our expert panel will include a variety of perspectives and the aim is to provide pragmatic solutions and actionable advice to make virtual trials a realistic option for your study needs. We’ll discuss strategic and tactical needs to help
you determine how to navigate and implement virtual and decentralized options to drive your pipeline goals. Topics to be discussed include:
- Discuss the settings for virtual trials and help define best fit options for study needs.
- How and when does the regulatory strategy get set to enable a successful filing?
- What are the challenges to drive both site and patient participation in virtual trials?
- What are the timeline and cost differences in planning for and executing virtual trial components?
- What are the key lessons learned from those who have been early adopters and champions?
1:05 Transition to Lunch
1:10 SCOPE Send Off Luncheon Presentation: Is Your Paper Protocol Really Fit for Purpose?
Brendan Buckley, MD, DPhil, Chief Medical Officer, Teckro
When did you last use a telephone directory for a restaurant booking? It might seem absurd to flip through a dated paper directory when the latest information is always searchable online. Why, then, are we still using paper protocols to manage
clinical trials? It’s time we bring clinical trials into the digital era. Join this session to find out how to transform your protocol into actionable data for research staff, study teams and CROs.
1:40 Closing Remarks
1:45 SCOPE Summit 2020 Adjourns
Day 1 | Day 2 | Download Brochure